Focus on TDM: Enabling the Detection of Both Large and Small Molecule Drugs on a Single Platform
Therapeutic Drug Monitoring (TDM) is a critical technical foundation for precision medicine. Diagreat Bio has long been dedicated to the field of drug concentration monitoring and has achieved the detection of both small-molecule and large-molecule drugs on a single platform—enabling the detection of both traditional small-molecule drugs and large-molecule monoclonal antibodies on the same platform, thereby providing a comprehensive data foundation for personalized precision medicine.
Three Core Products Build a Closed-Loop TDM Workflow
At this year’s CMEF, Diagreat Bio will showcase three core products under its “End-to-End Smart Solution for Drug Concentration Monitoring” model:
MIPD Model-Guided Drug Concentration Prediction System
Model-Driven · Laying a Solid Foundation for the Rational Use of Medications
Addressing Pain Points · Personalized, Targeted Drug Delivery
Visual Empowerment · Balancing Efficacy and Safety
Chemiluminescence TDM Detection Platform
Fully Automated, High-Throughput · Reduces Human ErrorSimultaneous
TDM Testing of Large and Small Molecules · Reduces Costs and Improves Efficiency
EQA Grouped Comparison · Reliable, Traceable Results
DP120 Fully Automatic Sample Preparation System for Drug Concentration Monitoring
Fully Automated Processing · High Efficiency and Labor Savings
Batch Size of 60 Samples · Standardization to Reduce Variation
Intelligent, Modular Control · Flexible and Controllable Workflow
The testing menu covers a wide range of drug categories, including anti-infectives, immunosuppressants, psychotropic drugs, anticancer agents, bronchodilators, antituberculosis drugs, large-molecule monoclonal antibodies, and cardiac glycosides, with a commitment to bringing “guidance for precise medication use and support for safe medical care” to clinical practice.
Comprehensive coverage across multiple product categories, serving all clinical and industrial scenarios
In addition to TDM, Diagreat Bio’s product portfolio includes a fluorescent immunoassay series, routine chemiluminescence assays, a biochemistry series , and an IVD raw materials series. The company also provides supporting services such as raw material supply, OEM manufacturing, and product registration to meet the diverse needs of the clinical testing and in vitro diagnostics industries.
October in Beijing brings the perfect autumn weather. Diagreat Bio looks forward to seeing you at Booth A2D10.